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BACKGROUND: The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib
with gemcitabine obtained FDA approval for treating patients with pancreatic cancer. However, duration of response is often limited
and there is currently no reliable predictive marker.
METHODS: We determined the sensitivity of a panel of human pancreatic tumour cell lines to treatment with afatinib, erlotinib,
monoclonal antibody (mAb) ICR62, and gemcitabine, using the Sulforhodamine B colorimetric assay. The effect of these agents on
cell signalling and cell-cycle distribution was determined by western blot and flow cytometry, respectively.
RESULTS: At 200nM, ICR62 had no effect on growth of these tumour cells with the exception of BxPC-3 cells. BxPC-3 cells were also
sensitive to treatment with afatinib and erlotinib with respective IC50 values of 11 and 1200nM. Compared with erlotinib, afatinib was
also more effective in inhibiting the growth of the other human pancreatic tumour cell lines and in blocking the EGF-induced
phosphorylation of tyrosine, EGFR, MAPK, and AKT. When tested in BxPC-3 xenografts, afatinib induced significant delay in tumour
growth.
CONCLUSION: The superiority of afatinib in this study encourages further investigation on the therapeutic potential of afatinib as a single
agent or in combination with gemcitabine in pancreatic cancer.
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Pancreatic cancer remains one of the most aggressive types of human
cancer. Despite major advances in imaging technologies, surgery,
chemotherapy and radiotherapy in the last few decades, survival
rates for patients with pancreatic cancer are extremely poor with a
mean 5-year survival rate of o10% (Klapman and Malafa, 2008).
Worldwide, pancreatic cancer is responsible for 4200000 deaths
each year (Parkin et al, 2005; Ferlay et al, 2010). In the United States
alone, there were an estimated 43140 new cases of pancreatic cancer
and 36800 deaths in 2010 (Jemal et al, 2010). One major contributing
factor to mortality is the lack of specific marker(s) for the early
detection of pancreatic cancer. Indeed, B80% of pancreatic cancer
cases are diagnosed at an advanced stage of the disease and these
patients are intrinsically resistant to treatment with radiation and
chemotherapy (Li and Saif, 2009).
Since the early 1980s, aberrant expression and activation of
epidermal growth factor receptor (EGFR) (ErbB1/HER1), which is
the prototype member of the class-I growth factor receptor
tyrosine kinase family (also called ErbB/HER family), has been
reported in a wide range of human malignancies and in some cases
it has been associated with poor prognosis (Modjtahedi and Dean,
1994; Nicholson et al, 2001; Normanno et al, 2006; Zhang et al,
2007). The ErbB/HER family consists of three additional members
namely ErbB2 (neu/HER2), ErbB3 (HER3) and ErbB4 (HER4)
(Normanno et al, 2006). The binding of a HER ligand to its
respective receptor leads to conformational changes in the
receptor’s extracellular domain which allow the formation of
homo- and/or heterodimers between different members of the
ErbB family. Dimerisation results in auto- and transphospho-
rylation of specific tyrosine residues in the cytoplasmic region of
the receptors, which in turn leads to the activation of numerous
downstream mediator molecules. These downstream proteins
mediate the activation of several signalling pathways the most
significant of which are the PI3K/Akt and the RAS/RAF/MAPK
pathways. These have an important role in the regulation of
cellular processes such as cell proliferation, differentiation and
survival (Olayioye et al, 2000; Yarden, 2001; Normanno et al,
2006). The association between aberrant activation of ErbB
receptor family and a poor prognosis in a number of studies has
led to the strategic development and approval of several ErbB
targeted agents for the treatment of several human malignancies.
These include anti-HER monoclonal antibodies (mAbs) like
trastuzumab, cetuximab and panitunumab and small molecule
HER tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib
and lapatinib (Zhang et al, 2007). Since the introduction of
gemcitabine only the combination with erlotinib has been tested
and approved for the treatment of patients with advanced
pancreatic cancer (Kelley and Ko, 2008). This combination led to
a marginal but statistically significant improvement in overall
survival (6.24 months in combination vs 5.91 months with
gemcitabine alone) and an increase in 1-year survival rate (23%
with the combination vs 17% with gemcitabine alone; Moore et al,
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s2007). Despite the clinical benefit for a small fraction of treated
patients, the majority of pancreatic cancer patients simply do not
respond to treatment with erlotinib or acquire resistance following
a few rounds of drug administration. Therefore, it is imperative
not only to develop novel and more effective therapeutic agents for
the treatment of pancreatic cancer, but also to identify those
factors that are responsible for the poor response or development
of resistance to the different types of therapies.
We reported previously the development of a large panel of anti-
EGFR mAbs of which ICR62 was found to inhibit the binding of
ligands to the EGFR and the subsequent ligand-induced EGFR
tyrosine phosphorylation and activation of downstream cell
signalling pathways (e.g., MAPK and PI3-K phosphorylation;
Modjtahedi et al, 1993, 2003; Cunningham, 2006). In addition,
mAb ICR62 has been shown to inhibit the growth of the EGFR
overexpressing cell lines both in vitro and in vivo (Modjtahedi
et al, 1993, 1996; Cunningham, 2006). Since small molecule TKIs
and mAbs target two different domains of the receptor (extra-
cellular and intracellular domains, respectively), a combination of
these two strategies may be more effective than treatment with
single agents. Indeed, in some studies, dual targeting of the EGFR
with a combination of the two approaches (i.e., cetuximab with
erlotinib or gefitinib) was shown to be superior to treatment with a
single agent (Huang et al, 2004; Matar, 2004; Regales et al, 2009).
Unlike the reversible EGFR TKIs (gefitinib or erlotinib), afatinib
(BIBW 2992) is an anilino-quinazoline derivative that was
designed to covalently bind and irreversibly inhibit the ErbB
family members EGFR, HER2 and HER4 (Solca, 2007; Minkovsky
and Berezov, 2008; Perera et al, 2009; Nam et al, 2011). Afatinib
was shown to have superior growth inhibitory efficacy compared
with erlotinib in preclinical lung cancer models and in particular
against lung cancer cells which display the EGFR (T790M) muta-
tion and which are resistant to treatment with erlotinib or gefitinib
(Li et al, 2008). In this study, we investigated the sensitivity of
seven human pancreatic tumour cell lines to treatment with
mAb ICR62, afatinib, erlotinib and gemcitabine used alone or in
combinations. In addition, we investigated whether there was an
association between the expression level of ErbB family members
(EGFR, HER-2, HER-3 and HER-4) and response to treatment with
the anti-HER agents as well as the effect of these agents on the
cell-cycle distribution of pancreatic cancer cell lines.
MATERIALS AND METHODS
Tumour cell lines
A panel of seven human pancreatic cancer cell lines was used in
this study including BxPC-3, PT-45, MiaPaCa-2, PANC-1, AsPc-1,
Capan-1 and FA6. AsPc-1 and Capan-1 cell lines were kindly
provided by Dr Charlotte Edling (Blizard Institute of Cell and
Molecular Science, Barts and The London School of Medicine and
Dentistry). Other pancreatic tumour cell lines (PANC-1, Mia PaCa2
and BxPC-3) were purchased from European Collection of Cell
Cultures (ECACC, Porton Down, UK). The EGFR overexpressing
(MDA-MB468), HER-2 overexpressing (SKBR3) and MCF-7 hu-
man breast tumour cell lines were used as controls in this study
(Cunningham, 2006). All cell lines were cultured routinely at 371C
in a humidified atmosphere (5% CO2). MiaPaCa-2 and PANC-1
were cultured in Dulbecco’s Modified Eagle’s Medium (Sigma-
Aldrich, Gillingham, UK) supplemented with 10% Fetal Bovine
Serum (FBS) (heat inactivated; PAA Laboratories, Yeovil, UK)
and antibiotics penicillin (50units per ml), streptomycin
(0.05mgml
 1) and neomycin (0.1mgml
 1) (Sigma-Aldrich).
BxPC-3, PT-45, AsPc-1, Capan-1 and FA6 were cultured in
RPMI-1640 medium (Sigma-Aldrich) supplemented with 10%
FBS, antibiotics penicillin, streptomycin and neomycin and 2mM
Glutamine (Sigma-Aldrich).
Antibodies and other reagents
mAB ICR62 (IgG2b) was raised against the external domain of
the EGFR on the breast cancer cell line MDA-MB468 as described
previously (Modjtahedi et al, 1993). The primary mouse anti-
bodies used in this study, HM50.67A and HM43.16B, were raised
against the external domain of the HER-2 and EGFR, respectively
(Cunningham, 2006). Mouse mAbs MAB3481 (anti-HER-3) and
MAB11311 (anti-HER-4) were purchased from R&D Systems
(Abingdon, UK). Secondary FITC-conjugated rabbit anti-mouse
mAb STAR9B was obtained from AbD Serotec (Kidlington, UK).
Erlotinib was kindly provided by OSI Pharmaceuticals (Farmingdale,
NY, USA). Gemcitabine was acquired from Healthcare at Home
(Burton on Trent, UK) and the irreversible ErbB family blocker
afatinib was developed by Boehringer Ingelheim (Vienna, Austria).
Cell surface expression of HER family members
The cell surface expression of all HER family members (EGFR,
HER-2, HER-3 and HER-4) was assessed by flow cytometry as
described previously (Cunningham, 2006). Briefly, B1 10
6 cells
were suspended in 1ml of growth medium supplemented with 2%
FBS and incubated for 1h by rotation at 41C, with medium alone
or medium containing 10mgml
 1 of mouse primary antibodies.
Cancer cells were then washed three times by centrifugation at
1200r.p.m. (264g) for 5min, resuspended in 2% FBS growth
medium and then incubated for 1h by rotation at 41C with FITC-
conjugated rabbit anti-mouse IgG STAR9B (AbD Serotec) antibody
(1:200 dilution). Following incubation with the secondary anti-
body, cells were washed three times by centrifugation and finally
resuspended in 0.5ml of FACS Flow buffer (Becton Dickinson Ltd,
Oxford, UK). A minimum of 10000 events were recorded by
excitation with an argon laser at 488nm using the FL-1 detector
(525nm) of a BD FACsCalibur flow cytometer (Becton Dickinson
Ltd). Mean fluorescence Intensity values were calculated using the
CellQuest Pro software (Becton Dickinson Ltd) and compared with
those of negative controls.
Growth inhibition studies
The effect of the various agents on the growth of human cancer cell
lines was investigated using the Sulforhodamine B (SRB; Sigma-
Aldrich) colorimetric assay. Briefly, tumour cells were seeded at a
density of 5 10
3cells per well in 100ml of growth medium (RPMI-
1640 or DMEM according to the cell line) supplemented with 2%
FBS in a 96-well plate. After 4h incubation at 371C (in a humidified
atmosphere, in 5% CO2), 100ml aliquots of doubling dilutions of the
agents were added to triplicate wells. Cells were incubated at 371C
(3–5 days depending on the cell line) until the control cells (no
treatment) became confluent. Tumour cells were then fixed with
10% trichloroacetic acid (Fisher Scientific, Loughborough, UK) for
1h, washed five times with tap water, air dried and stained with
0.4% SRB in 1% acetic acid for 1h. Following that, cells were
washed with 1% acetic acid, air dried and the SRB stain was
solubilised with 10mM Tris-base (100ml per well; Fisher Scientific).
The absorbance of each well was measured at 565nm using an
Epoch plate reader (Biotek, Potton, UK). For the determination of
the initial number of cells (before treatment), an extra plate was set
up and processed similarly after 4h incubation at 371C without the
inhibitors. Growth as a percentage of control was determined from
the formula:
%Growth ¼
B   A
C   A
 100
where: A¼Absorbance at 565nm (A565nm) before treatment,
B¼A565nm after treatment with inhibitors and C¼A565nm after
incubation in medium alone. The 50% inhibitory concentration of
cell growth (IC50) was calculated by non-linear least squares curve
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sfitting (Four parameter analysis, log (inhibitor) vs response,
variable slope) using Gen5 software (Biotek).
Determination of combination index
The growth inhibitory effect of the agents under investigation was
also assessed when used in combination. Interactions between the
different agents were assessed, using the combination index (CI) as
described by Chou and Talalay (1984). For each combination, the
two drugs were mixed at their 4 IC50 followed by eight doubling
dilutions. Combination index o0.9 indicates a synergistic effect
while CI between 0.90 and 1.10 denotes an additive effect.
Combination index 41.1 indicates antagonistic effects. Data
analysis was performed using the Calcusyn software (Biosoft,
Cambridge, UK).
Cell-cycle distribution analysis
The effect of HER inhibitors and gemcitabine on the cell-cycle
distribution of the cancer cell lines was investigated using flow
cytometry. Briefly, B2.5 10
5 cells were seeded to 25cm
2 flasks
containing 10ml of 2% FBS growth medium and the inhibitors at
different concentrations or control medium. Once the cells contain-
ing only medium were almost confluent, treated cells were harvested
and pooled together with the supernatant. Cancer cells were washed
three times with cold PBS by centrifugation at 1200r.p.m. (264g)f o r
5min. The final cell pellet was resuspended in 200mlo fc o l dP B S ,
fixed by the addition of 70% ethanol overnight at 41C. Tumour
cells were then collected by centrifugation (264g for 5min) washed
once with PBS and incubated with PI/RNAse mix (500mlp e r
10
6cells) (Becton Dickinson Ltd) for 35min at room temperature.
A minimum of 10000 events were recorded by excitation with an
argon laser at 488nm using the FL-3 detector (620nm) of a BD
FACsCalibur flow cytometer (Becton Dickinson Ltd) and analysed
using the CellQuest Pro software (Becton Dickinson Ltd).
Western blot analysis
Cancer cells were grown to near-confluency in 6-well culture plates
containing 5ml of 10% FBS RPMI growth medium. Cells were
washed once with 5ml of RPMI/0.5% FBS and incubated in 5ml of
RPMI/0.5% FBS containing no inhibitor, afatinib (400nM), erlotinib
(400nM), ICR62 (400nM) or gemcitabine (100nM)f o r2 4ha t3 71C.
Following incubation with the inhibitors, cells were stimulated with
20nM of EGF (Austral Biologicals, San Ramon, CA, USA) for 15min
and washed once with 5ml of PBS. Cancer cells were lysed using
400ml of Lysis buffer (Invitrogen, Paisley, UK) containing a
protease inhibitor cocktail (Sigma-Aldrich) and cell lysates were
heated at 901C for 4min. Protein samples (20mg) were separated on
4–12% Bis-Tris gels (Invitrogen) using the XCell II Surelock Mini-
Cell system (Invitrogen) and transferred onto polyvinylidene
difluoride (PVDF) membranes using the XCell II Mini-Cell Blot
Module kit (Invitrogen). The PVDF membranes were probed with
antibodies using the SNAP i.d System (Millipore, Watford, UK).
Mouse antibodies against phospho-Tyr-100 and b-actin were
purchased from Cell Signalling (Hitchin, UK), while anti-EGFR
antibody from Sigma-Aldrich. Rabbit antibodies against Akt,
MAPK and phospho-MAPK (Thr202/Tyr204) were purchased from
Cell Signalling while anti-phospho EGFR (Tyr1173) and anti-
phospho Akt (S473) rabbit antibodies were obtained from
Biosource (Paisley, UK). The specific signals were detected using
the WesternBreeze chemiluminescence kit (alkaline phosphatase-
conjugated secondary antibody) (Invitrogen).
In vivo xenograft experiments
Five- to six-week-old female athymic BomTac:NMRI-Foxn1
nu mice
were maintained under specific pathogen-free conditions. All
experiments complied with the Declaration of Helsinki and
European Policy Legislations (FELASA and GV-SOLAS) on the
Care and Use of Laboratory Animals. After acclimatisation mice
were inoculated subcutaneously with 1 10
6 BxPC-3 cells (in
100ml matrigel) into the right flank of the animal. After tumours
reached an average volume of 50–100mm
3, the mice were
randomised and treated orally daily with 15mgkg
 1 afatinib or
vehicle control on the basis of individual weights. Tumours were
measured three times a week with calipers, and tumour volumes
were calculated by the formula p/6 length (width)
2. Afatinib
was formulated in 1.8% HP-beta-CD (Hydroxypropyl-b-cyclo-
dextrin, Sigma-Aldrich), 5% of a 10% acetic acid stock and
aqueous Natrosol (0.5%), and administered by intragastral gavage.
The administration volume was 10mlkg
 1 body weight.
Statistical analysis
Linear regression analysis was used for the assessment of the
relationship between the HER family receptors expression and
response to treatment with afatinib. The unpaired two-tailed
Student’s t-test was used for comparing mean values between two
groups. Data are presented as mean±s.d. Po0.05 was considered
statistically significant.
RESULTS
Cell surface expression of HER family members
We determined the expression levels of HER family of receptors in
seven different pancreatic cancer cell lines using flow cytometry. All
pancreatic tumour cell lines were found to be positive for both
EGFR and HER-2 (Table 1). Compared with the MFI value of 415 in
the positive-control EGFR overexpressing cell line MDA-MB468, the
MFI values for the EGFR in this panel of human pancreatic tumour
cell lines were lower and ranged from 34.54 (FA6) to 181.82 (PT-45)
(Table 1). Similarly, compared with the MFI value of 831 in control
SKBR3 cells, the MFI values for HER-2 expression in pancreatic
tumour cells were much lower and ranged from 8.65 (FA6) to 29.25
(MiaPaCa-2) (Table 1). Most of the human pancreatic tumour cell
lines were found to be HER-4 negative while expressing extremely
low or undetectable levels of HER-3 (Table 1).
Growth response of human pancreatic tumour cells to
treatment with anti-EGFR mAb ICR62, erlotinib, afatinib
and gemcitabine
Of the seven human pancreatic tumour cell lines examined, BxPC-3
cells were the most sensitive cell line to treatment with afatinib
Table 1 Expression (MFI) of HER family members (EGFR, HER-2, HER-3
and HER-4) in human pancreatic cancer cell lines
Mean fluorescence intensity (MFI)
Cell line Control EGFR HER-2 HER-3 HER-4
Capan-1 4.2±0.7 138.5±15.2 28.9±3.1 7.4±0.7 4.9±0.4
PT-45 2.9±0.6 184.7±21.1 21±1.9 6.1±0.4 3.9±0.3
PANC-1 3±0.2 119.7±7.6 13.6±0.6 3.4±0.1 4.1±0.2
BxPC-3 8±1.2 98.0±12.7 29.4±3.3 15.5±1.5 9.8±0.5
MiaPaCa-2 3.7±0.3 39.5±3 32.9±3.8 4±0.3 4.4±0.3
AsPc-1 3.6±0.7 97.4±12.8 19±2 5.9±0.5 4.1±1.3
FA6 5.9±0.4 40.4±8.2 14.5±1.9 9.8±1.4 5.5±0.5
SKBR3 (breast) 4.3±0.2 N/A 831.3±74.6 21.2±8.7 N/A
MDA-MB468
(breast)
3.8±0.3 415.3±42 N/A N/A N/A
MCF-7 (breast) 3.5±0.3 N/A N/A N/A 24.6±2.3
Abbreviation: EGFR¼epidermal growth factor receptor. Breast cancer cell lines
SKBR3, MDA-MB468 and MCF-7 were used as positive controls for HER-2/HER-3,
EGFR and HER-4 receptors, respectively.
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swith an IC50 value of 11nM. The growth of other human pancreatic
tumour cells was also inhibited by afatinib with IC50 values ranging
from 367nM (AsPc-1) to 1.37mM (FA6) (Table 2; Figure 1B). In
addition, BxPC-3 cells were the most sensitive to treatment with
erlotinib with an IC50 value of 1.26mM followed by AsPc-1 with an
IC50 value of 5.8mM (Table 2; Figure 1C). The mAb ICR62 has
previously been shown to completely inhibit the growth of EGFR
overexpressing tumour cell lines HN5 and DiFi in vitro in the low
nanomolar range. In these experiments, ICR62 did not have any
effect on the growth of the human pancreatic tumour cell lines
tested at 200nM (Figure 1D; Cunningham, 2006). The only
exception was BxPC-3 cells, which were growth inhibited by
13%, however, with no statistical significance (P¼0.061,
Figure 1D). Gemcitabine inhibited the growth of all human
pancreatic tumour cell lines with IC50 values ranging from 5nM
(FA6) to 105nM (Capan-1) (Figure 1A; Table 2). Morphology of
BxPC-3 cells following the treatment with growth inhibitory
concentrations of erlotinib, afatinib and gemcitabine is presented
in Figure 2. Next, we investigated the interactions between the
different agents when used in combination. Median effect analysis
showed that a combination of afatinib or erlotinib with
gemcitabine led to a synergistic effect (CIo0.9) in the majority
of cell lines tested (Table 2). We found no enhancement of growth
inhibition following treatment with a combination of ICR62 with
afatinib or gemcitabine or erlotinib in these in vitro models (data
not shown).
Correlation of HER family member expression and
sensitivity to ErbB inhibitors
Linear regression analysis was carried out in order to determine
whether sensitivity to treatment with ErbB inhibitors was
dependent on the expression level of the HER receptors. There
was no correlation between the expression of EGFR (R¼0.010,
P¼0.982) or HER-2 (R¼0.458, P¼0.301) and the IC50 values for
afatinib nor any association between EGFR expression levels and
response to treatment with erlotinib (R¼0.153, P¼0.743) or other
members of HER family.
Cell-cycle distribution analyses
We examined the changes in cell-cycle distribution of the
pancreatic cancer cells of various origins after treatment with
afatinib and gemcitabine. Treatment with gemcitabine increased
the proportion of pancreatic tumour cells in the subG1 phase
(apoptotic/dead cells) of the cell cycle and this was accompanied
by a significant increase in the percentage of cells in S phase
consistent with inhibition of DNA synthesis (Table 3). For
example, treatment of BxPC-3 cells with gemcitabine increased
the proportion of cells in the subG1 phase from 9% to 36% and in
the S phase from 22% to 46%, respectively (Table 3). In contrast,
treatment of human pancreatic cells with afatinib increased the
proportion of cells in subG1 phase of the cell cycle, accompanied
by a decrease in the percentage of cells in G0/G1 phase of the cell
cycle in the majority of cell lines investigated. Erlotinib had a
similar effect to afatinib on the cell-cycle distribution of the two
cell lines examined (BxPC-3 and AsPc-1) (Table 3).
Effect of anti-EGFR mAb ICR62, erlotinib, afatinib
and gemcitabine treatment on EGF-induced tyrosine
phosphorylation of the proteins in BxPC-3 cells
In contrast to gemcitabine, all three inhibitors blocked the EGF-
induced tyrosine phosphorylation of EGFR and the phosphoryla-
tion of the tyrosine residue at position 1173 of the EGFR in BxPC3
cells. However, of the three inhibitors, afatinib was the only agent
that successfully blocked the EGF-induced phosphorylation of
both MAPK (ERK 1/2) and Akt (Figure 2B).
Xenograft experiments in mice
In vivo, afatinib showed potent anti-tumour activity in the BxPC-3
human pancreatic xenograft model. Daily administration of
15mgkg
 1 afatinib as a single agent to mice carrying established
tumours did not induce long-lasting tumour regressions but
significantly delayed tumour growth with a T/C value of 18% and a
tumour growth inhibition (TGI) value of 89% as assessed at the
end of the experiment (Figure 3).
DISCUSSION
Currently, among the several ErbB-targeting inhibitors developed,
only the reversible EGFR TKI erlotinib has been approved in
combination with gemcitabine for the treatment of patients with
pancreatic cancer (Mendelsohn and Baselga, 2006; Ciardiello and
Tortora, 2008; Modjtahedi and Essapen, 2009). While erlotinib
improves survival, the duration of response is often limited and
the majority of patients acquire resistance following a few rounds
of treatment. Unlike first-generation reversible EGFR TKIs such as
erlotinib and gefitinib, afatinib covalently binds and irreversibly
inhibits the tyrosine kinase activity of all ErbB family members
and is therefore expected to block both partners in the ErbB
receptor dimer. This should result in a more effective signalling
blockade and greater anti-tumour efficacy when compared with
agents targeting EGFR alone. In this study, for the first time, we
investigated the growth response of a panel of human pancreatic
tumour cells to treatment with afatinib, ICR62, erlotinib and
gemcitabine when used alone or in combination. We also
Table 2 IC50 values for erlotinib, afatinib and gemcitabine in pancreatic cancer cell lines assessed by the SRB colorimetric assay and combination index (CI)
values of gemcitabine plus afatinib or erlotinib in pancreatic cancer cell lines
IC50 value
Afatinib+gemcitabine
combination index (effect)
Erlotinib+gemcitabine
combination index (effect) Cell line Erlotinib Afatinib Gemcitabine
BxPC-3 1.26mM 11nM 7.4nM 0.31 (Synergism) 0.46 (Synergism)
AsPc-1 5.8mM 367nM 87.3nM 0.62 (Synergism) 0.69 (Synergism)
FA6 420mM 1.37mM 5.23nM 0.85 (Slight synergism) N/A
PANC-1 420mM 966nM 21.4nM 0.73 (Moderate synergism) N/A
Capan-1 420mM 781nM 104.9nM 0.88 (Slight synergism) 0.66 (Synergism)
MiaPaCa-2 420mM 709nM 6.4nM 1.25 (Moderate antagonism) 1.30 (Moderate antagonism)
PT-45 420mM 1.02mM 14.3nM 1.40 (Moderate antagonism) 0.54 (Synergism)
Abbreviations: N/A¼not available; IC50¼50% inhibitory concentration; SRB¼Sulforhodamine B. Interpretation of the results was based on the proposed descriptions for
presenting the degrees of antagonism or synergism by Calcusyn software
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sinvestigated whether there was any association between the
expression of HER family members and response to treatment
with ErbB inhibitors.
We reported previously that, at concentrations 43.2nM, mAb
ICR62 inhibits completely the growth of the EGFR overexpressing
cell lines HN5 and DiFi in vitro (Cunningham, 2006). In the
present experiments, at a maximum concentration of 200nM, mAb
ICR62 had no significant effect on the growth of any of the human
pancreatic tumour cell lines investigated (Figure 1D). This may be
due to the lower expression of EGFR in these pancreatic cell lines
compared with the EGFR expression in HN5 or DiFi cells
(Modjtahedi et al, 1993; Cunningham, 2006). Another possible
explanation for the lack of response to treatment with mAb ICR62
could be the presence of autocrine loops. Previous studies have
shown that EGFR ligands may compete with mAbs for binding to
the receptor and reduce their anti-proliferative activity (Castillo,
2004). In another study, Buchsbaum and colleagues investigated
the effect of anti-EGFR mAb erbitux on the proliferation of BxPC-3
and MiaPaCa-2 cells. They found that while exposure to erbitux for
96h resulted in a 17% reduction in proliferation of BxPC-3 cells, it
did not have any inhibitory effect on MiaPaCa-2 cells(Buchsbaum
et al, 2002). Of all cell lines examined in our study, mAb ICR62
only inhibited the growth of BxPC-3 cells by 13%, but this was not
statistically significant (P¼0.061, Figure 1D) and blocked the EGF-
induced tyrosine phosphorylation of EGFR in these cells
(Figure 2B).
Unlike mAb ICR62 which targets the extracellular ligand
binding domain of the EGFR, afatinib is an irreversible inhibitor
of the ErbB family (Solca, 2007; Berezov, 2008; Minkovsky and
Berezov, 2008; Nam et al, 2011). Afatinib was found to inhibit the
growth of all seven human pancreatic cancer cell lines with IC50
values ranging from 11nM (BxPC3) to 1.37mM (FA6) (Figure 1B;
Table 2). However, the majority of cell lines were found to
be insensitive to treatment with erlotinib with only BxPC-3
and AsPc-1 cell lines responding to treatment with this agent.
The IC50 values were 1.26 and 5.8mM for BxPC-3 and AsPc-1 cells,
respectively (Table 2). In agreement with our findings in a
previous study, Buck et al (2006) investigated the sensitivity
of three pancreatic tumour cell lines, BxPC-3, MiaPaCa-2 and
PANC-1 to treatment with erlotinib and of these only BxPC-3
was marginally sensitive to treatment with erlotinib with an IC50
value of 1.3mM. In another study, erlotinib was found to inhibit
the growth of BxPC-3 and Capan-1 cells with IC50 values of 7.6
and 420mM, respectively (Cai et al, 2010). This comparative
data analysis suggests that afatinib inhibits more potently the
proliferation of pancreatic cancer cells in vitro. In addition, of all
agents investigated, only afatinib inhibited the EGF-induced
phosphorylation of MAPK (ERK 1/2) and Akt in BxPc-3 cells.
Several studies have evaluated the anti-tumour activity of
lapatinib, which is a reversible dual EGFR/HER-2 TKI. In one
study, Komoto et al (2010) found that lapatinib, at the maximum
concentration of 30mM, inhibited the growth of Capan-1, Capan-2,
PANC-1 and MiaPaCa-2 by o8%. Recently, in a recent phase II
study 125 patients with metastatic pancreatic cancer were treated
with 1500mg of Lapatinib per day and 1gm
 2 per week of
gemcitabine for 3 weeks until the disease progression. However, no
therapeutic benefit was reported for such combination (Safran
et al, 2011).
In this study, we found no correlation between the expression
level of EGFR (R¼0.010, P¼0.982) or HER-2 (R¼0.458,
P¼0.301) and response to treatment with afatinib. Similarly,
Komoto et al (2010) found that there was no statistically significant
association between EGFR or HER-2 expression and the in vivo
anti-tumour effect of the dual EGFR/HER-2 TKI lapatinib. These
findings suggest that ErbB receptor expression levels are not of
major relevance and may not be used as predictive biomarkers to
identify responding models in vitro. Other factors such as the
mutational status of ErbB family receptors or downstream
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Figure 1 Effect of doubling dilutions of gemcitabine (A), afatinib (B)o r
erlotinib (C) on the growth of human pancreatic cancer cells. Tumour cells
were grown in growth medium (2% FBS) with the inhibitors or medium
alone until control cells (only medium) were confluent. Cancer cell
proliferation was calculated as a percentage of control cell growth, as
described in the Materials and Methods. Each point represents the
mean±s.d. (D) The effect of gemcitabine at 100nM, ICR62 at 200nM and
erlotinib or afatinib at 1.5mM in pancreatic cancer cell lines (as percentage
of control growth) is shown (columns, mean of triplicate values; bars,
±s.d.).
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smolecules like K-RAS may be implicated in the sensitivity to ErbB
inhibition. For example, in glioblastoma and non-small-cell lung
carcinoma (NSCLC) patients the presence of EGFRvIII or T790M
EGFR was found to be associated with resistance to treatment with
gefitinib and erlotinib, respectively (Learn et al, 2004; Kobayashi
et al, 2005; Pao et al, 2005). In addition, K-Ras mutations, which
lead to the activation of the K-RAS protein in an EGFR-
independent manner, have been associated with resistance to
treatment with EGFR targeting mAbs in NSCLC and metastatic
colorectal cancer patients (Linardou et al, 2008). While EGFR gene
mutation is a rare phenomenon in pancreatic cancer, the presence
of K-Ras mutations is a very common event and occurs in 75–95%
pancreatic cancer patients (Hruban et al, 1993; Berrozpe et al,
1994; Laghi et al, 2002; Immervoll et al, 2006). It is noteworthy that
of all the cell lines investigated in this study, BxPC-3 is the only
one which carries a wild-type K-Ras gene which could explain its
greater sensitivity to afatinib (IC50¼11nM) and erlotinib
(IC50¼1.26mM) treatment compared with the rest of the tested
cell lines (Table 2; Sipos et al, 2003). Further studies aimed at
replacing wild-type K-Ras with mutant K-Ras in isogenic models
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Figure 2 (A) Morphology of BxPC-3 cells following growth inhibitory concentrations of erlotinib, afatinib and gemcitabine (mM) compared with treatment
with medium alone (original magnification  20). (B) Effect of afatinib, erlotinib and ICR62 on EGF-induced phosphorylation of tyrosine, EGFR, MAPK and
Akt in BxPC-3 cells. BxPC-3 cells were cultured to near-confluency in growth medium containing 10% FBS, then treated in 0.1% FBS medium containing
400nM of TKI, mAb ICR62 (400nM) or gemcitabine (100nM) for 24h at 371C. Following incubation with the inhibitors, cells were stimulated with 20nM of
EGF for 15min. Then, treated cells were lysed, protein samples were separated by SDS–PAGE, transferred onto PVDF membranes, an probed with
antibodies specific for the molecule of interest.
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swill be necessary to substantiate this hypothesis. The BxPC-3
model could be suitable for such activities as in vitro observations
can be verified in the in vivo setting. In this model, afatinib as a
single agent demonstrated significant anti-tumour activity achiev-
ing an 89% TGI at the end of the experiment (day 24) with a T/C
value of 18% (Figure 3). For comparison, gemcitabine when tested
as a single agent, in the same model (different experiment) at a
dose of 150mgkg
 1 twice weekly for 4 weeks (day 28), also
induced tumour growth delay with a T/C value of 23%, thus
comparing in activity with afatinib (data not shown).
The combination potential of these agents was assessed in vitro.
While the addition of ICR62 to either afatinib or gemcitabine had
no additional growth inhibitory effect compared with treatment
with a single agent, a synergistic effect was observed in five of the
seven human pancreatic tumour cell lines when afatinib was used
in combination with gemcitabine (Table 2), thus generating a
rationale for assessing such combination in vivo. Similarly, the
combination of erlotinib with gemcitabine led to a synergistic
effect in the majority of cell lines tested (Table 2). The enhanced
growth inhibitory effect of the combination of ErbB inhibitors and
gemcitabine may be attributed to the different mode of action of
these agents. Cell-cycle distribution analyses demonstrated that
gemcitabine altered the cell cycle of the treated cells, resulting in
an increased subG1 cell population as well as an increase in cells in
S phase consistent with previous findings (Ng et al, 2000).
Although treatment of human pancreatic cells with afatinib or
erlotinib increased the population of cells in subG1 phase of the
cell cycle, a reduction in the percentage of cells in G0/G1 and G2/M
phases of the cell cycle was observed in the majority of the cell
lines (Table 3). Intriguingly, the in vitro combination of afatinib
with gemcitabine was also capable of producing moderate
antagonistic effects in two of the human pancreatic tumour cell
lines used in this study with CI values of 1.25 and 1.4 in MiaPaCa-2
and PT-45, respectively (Table 2). In addition, the combination of
erlotinib and gemcitabine produced antagonistic effects in
MiaPaCa-2 (Table 2). Antagonism has also been reported when
afatinib was combined with another cytotoxic drug (5-FU) in some
colorectal cancer cells (Khelwatty et al, 2011). The different
outcome of the same drug combination in different cell lines
indicates the complex nature of drug/drug interactions and
illustrates the elaborate biology behind these agents, which
simultaneously force cells to perform G1- and S-phase arrests.
Further investigations are required to understand the subtle
differences induced by the combination treatments in these
different pancreatic cancer models.
In conclusion, our results show that afatinib is effective at
inhibiting the growth of human pancreatic tumour cells and that it
potentiates the effect of gemcitabine in the majority of cell lines
examined. Taken together, our findings encourage future investi-
gation on the therapeutic potential of afatinib, as a single agent or
in combination with gemcitabine in pancreatic cancer.
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Table 3 Effect of afatinib, erlotinib and gemcitabine on the cell-cycle
distribution of pancreatic cancer cell lines
Cell line/treatment Sub-G1 G0/G1 S G2/M
BxPc-3
Control 8.7 57.3 21.9 12.2
Afatinib 21.8 50.1 16.5 9.9
Gemcitabine 35.5 11 46.3 5.6
Erlotinib 13.3 51.6 20.7 13.5
AsPC-1
Control 1 45.9 32 19.6
Afatinib 13.3 43.5 30.9 13.6
Gemcitabine 3.3 15.7 54.5 24.9
Erlotinib 8 44.8 31.7 14.5
Capan-1
Control 3.6 49.2 27.7 19.4
Afatinib 9.5 49.3 28.9 10.8
Gemcitabine 23 26.3 31.9 18.1
PT-45
Control 2.8 71.4 14.3 10.8
Afatinib 9 67.9 15.4 6.8
Gemcitabine 23.7 33.6 36.9 5.4
MiaPaCa-2
Control 6.5 74.6 9.1 8.7
Afatinib 15.1 45.9 19.6 17.6
Gemcitabine 9.1 34 33.4 20
PANC-1
Control 6.7 51.6 11.7 29.4
Afatinib 42.9 28 10.5 17.9
Gemcitabine 20.1 38.8 30.1 9.4
FA6
Control 15.2 50.5 22 11.5
Afatinib 27.1 37.9 23.7 8.2
Gemcitabine 26.1 40.4 25.2 9
Each population is expressed as a percentage of gated cells.
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Figure 3 Effect of afatinib on the growth of BxPC-3 xenografts. Mice
carrying established tumours (50–100mm
3) were treated orally, once daily
with 15mgkg
 1 afatinib. Graph (A) shows tumour growth kinetics and
insert (B) reports individual tumour volume on the last day of the
experiment (day 24).
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